Sodium Bicarbonate → 1-(3-Benzo[1,3]dioxol-5-ylmethylpiperazin-1-yl)-7-methoxyisoquinoline
反応式
[O:1]1[C:5]2[CH:6]=[CH:7][C:8]([CH2:10][CH:11]3[CH2:16][N:15]([C:17]4[C:26]5[C:21](=[CH:22][CH:23]=[C:24]([O:27][CH3:28])[CH:25]=5)[CH:20]=[CH:19][N:18]=4)[CH2:14][CH2:13][N:12]3C(OC(C)(C)C)=O)=[CH:9][C:4]=2[O:3][CH2:2]1.C(=O)([O-])O.[Na+]>Cl.O1CCOCC1>[O:1]1[C:5]2[CH:6]=[CH:7][C:8]([CH2:10][CH:11]3[NH:12][CH2:13][CH2:14][N:15]([C:17]4[C:26]5[C:21](=[CH:22][CH:23]=[C:24]([O:27][CH3:28])[CH:25]=5)[CH:20]=[CH:19][N:18]=4)[CH2:16]3)=[CH:9][C:4]=2[O:3][CH2:2]1参加物
4
実験手順
In 10 ml of 4N hydrochloric acid-dioxane solution, 150 mg of 1-(2-benzo[1,3]dioxol-5-ylmethyl-1-tert-butoxycarbonylpiperazin-4-yl)-7-methoxyisoquinoline as synthesized in the above step was added and stirred for 18 hours. The solution was neutralized with saturated aqueous sodium hydrogencarbonate solution, extracted with ethyl acetate, dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified on silica gel column chromatography (methanol:chloroform=1:9) to provide 69 mg (58%) of 1-(3-benzo[1,3]dioxol-5-ylmethylpiperazin-1-yl)-7-methoxyisoquinoline.